Viatris CEO Michael Goettler

Vi­a­tris plans across-the-board cuts that could en­dan­ger 9,000 work­ers, 15 plants in post-merg­er re­struc­tur­ing scheme

In the high-vol­ume gener­ics game, size mat­ters — and no one is quite so big as new gi­ant on the block Vi­a­tris, which launched last month. But size can al­so mean re­dun­dan­cy, and now Vi­a­tris is plot­ting a ma­jor re­struc­tur­ing to stream­line its op­er­a­tions and bot­tom line.

Just weeks af­ter merg­ing two gener­ics gi­ants in My­lan and Pfiz­er’s Up­john unit, new­co Vi­a­tris is gear­ing up for wide-rang­ing cut­backs that could elim­i­nate 20% of the com­bined firms’ glob­al work­force and shut­ter or sell off a clutch of man­u­fac­tur­ing fa­cil­i­ties around the world, ac­cord­ing to up­dat­ed plans Vi­a­tris un­veiled Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.